Please login to the form below

Not currently logged in
Email:
Password:

Therachon appoints new chief medical officer

Dr Maarten Kraan joins the company from AstraZeneca

Dr Maarten KraanBasel, Switzerland-based biotech company Therachon has appointed Dr Maarten Kraan as its new chief medical officer in a role that will see him focus on the clinical development of TA-46 - Therachon’s leading drug in development for achondroplasia.

Kraan has held numerous roles such as vice president, immunosciences at Bristol-Myers Squibb, vice president, head of clinical research and experimental development at Roche, and most recently as head of innovative medicines respiratory and inflammation at AstraZeneca.

Luca Santarelli, chief medical officer at Therachon, said: “Dr Kraan’s wealth of translational and drug development expertise is critical during this exciting time in our company’s growth. He will play a key role in guiding TA-46 from discovery into clinical development and helping us fulfill our mission of developing medicines for rare, genetic diseases.”

In addition to his new role Dr Kraan will continue to serve as an adjunct professor at Goteborg University in Sweden.

27th March 2017

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Origins - The Patient Focused Specialists

Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...

Latest intelligence

Biosimilars and beyond: innovating for improved patient outcomes
How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before...
World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...